Vanzacaftor

Extended indication	Cystic Fibrosis Participants 1 Year of Age and Older
Therapeutic value	No estimate possible yet
Registration phase	Clinical trials

Product

Active substance	Vanzacaftor
Domain	Lung diseases
Reason of inclusion	New medicine (specialité)
Main indication	Cystic fibrosis
Extended indication	Cystic Fibrosis Participants 1 Year of Age and Older
Manufacturer	Vertex
Portfolio holder	Vertex
Route of administration	Oral
Therapeutical formulation	Tablet
Budgetting framework	Extramural (GVS)
Additional remarks	CFTR modulation

Therapeutic value	No estimate possible yet

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.